{"id":26668,"date":"2024-10-18T08:30:00","date_gmt":"2024-10-18T15:30:00","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/?p=26668"},"modified":"2024-10-17T12:55:05","modified_gmt":"2024-10-17T19:55:05","slug":"ivig-for-multiple-myeloma-mm","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-multiple-myeloma-mm\/","title":{"rendered":"IgIV para el mieloma m\u00faltiple (MM)"},"content":{"rendered":"<p>La IgIV se utiliza como terapia de apoyo en pacientes con mieloma m\u00faltiple. El mieloma m\u00faltiple es un tipo raro de c\u00e1ncer de la sangre que se forma en las c\u00e9lulas plasm\u00e1ticas, un tipo de gl\u00f3bulo blanco que produce anticuerpos para combatir infecciones en condiciones normales.&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-045b3c94ff4724cb68801e4940692f8f\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga asistencia para el copago de IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\"> (877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<p>En pacientes con mieloma m\u00faltiple, las c\u00e9lulas plasm\u00e1ticas cancerosas no producen anticuerpos eficaces, lo que las hace m\u00e1s vulnerables a las infecciones. Seg\u00fan investigaciones, las infecciones recurrentes son una de las causas subyacentes de muerte en... <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S2152265021000537\">22% a 45%<\/a> de pacientes con mieloma m\u00faltiple.&nbsp;<\/p>\n\n\n\n<p>Los m\u00e9dicos generalmente recomiendan la terapia con IgIV para reducir las tasas de mortalidad y morbilidad en pacientes con mieloma m\u00faltiple.&nbsp;<\/p>\n\n\n\n<p>Repasemos los conceptos b\u00e1sicos del mieloma m\u00faltiple, incluidos sus efectos sobre el sistema inmunol\u00f3gico, as\u00ed como tambi\u00e9n c\u00f3mo la terapia con IgIV puede ayudar a los pacientes que padecen mieloma m\u00faltiple.&nbsp;<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-multiple-myeloma-mm\/#Basics_of_Multiple_Myeloma_and_How_It_Affects_the_Immune_System\" >Conceptos b\u00e1sicos del mieloma m\u00faltiple y c\u00f3mo afecta al sistema inmunitario<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-multiple-myeloma-mm\/#What_Is_the_Prevalence_of_Multiple_Myeloma_in_the_US\" >\u00bfCu\u00e1l es la prevalencia del mieloma m\u00faltiple en los EE. UU.?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-multiple-myeloma-mm\/#How_Can_IVIG_Therapy_Help_Multiple_Myeloma_Patients\" >\u00bfC\u00f3mo puede la terapia con IgIV ayudar a los pacientes con mieloma m\u00faltiple?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-multiple-myeloma-mm\/#How_Does_IVIG_Therapy_Work\" >\u00bfC\u00f3mo funciona la terapia con IgIV?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-multiple-myeloma-mm\/#What_Is_the_Standard_Dose_of_IVIG_for_Multiple_Myeloma_Patients\" >\u00bfCu\u00e1l es la dosis est\u00e1ndar de IgIV para pacientes con mieloma m\u00faltiple?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-multiple-myeloma-mm\/#Who_Can_Benefit_From_IVIG_Therapy\" >\u00bfQui\u00e9n puede beneficiarse de la terapia con IgIV?<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Basics_of_Multiple_Myeloma_and_How_It_Affects_the_Immune_System\"><\/span><strong>Conceptos b\u00e1sicos del mieloma m\u00faltiple y c\u00f3mo afecta al sistema inmunitario<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>El mieloma m\u00faltiple es un c\u00e1ncer que se origina en la m\u00e9dula \u00f3sea y afecta a las c\u00e9lulas plasm\u00e1ticas. Tambi\u00e9n se conoce como<strong><em> <\/em><\/strong>C\u00e1ncer de c\u00e9lulas plasm\u00e1ticas: una sola c\u00e9lula plasm\u00e1tica se vuelve cancerosa, se multiplica sin parar y se acumula en la m\u00e9dula \u00f3sea. Finalmente, las c\u00e9lulas plasm\u00e1ticas cancerosas (tambi\u00e9n conocidas como c\u00e9lulas de mieloma) desplazan a las c\u00e9lulas hematopoy\u00e9ticas sanas de la m\u00e9dula \u00f3sea.&nbsp;<\/p>\n\n\n\n<p>Adem\u00e1s, las c\u00e9lulas plasm\u00e1ticas cancerosas producen anticuerpos anormales e ineficaces llamados prote\u00ednas M que no pueden combatir las infecciones.&nbsp;<\/p>\n\n\n\n<p>Adem\u00e1s, los tratamientos para el mieloma, como la quimioterapia y los trasplantes de c\u00e9lulas madre, debilitan el sistema inmunitario del paciente. Estas terapias no solo destruyen las c\u00e9lulas cancerosas, sino tambi\u00e9n las sanas, lo que provoca un bajo recuento de c\u00e9lulas plasm\u00e1ticas sanas y niveles bajos de anticuerpos. Como resultado, los pacientes con mieloma m\u00faltiple se vuelven muy susceptibles a infecciones como la neumon\u00eda (infecci\u00f3n respiratoria).&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Is_the_Prevalence_of_Multiple_Myeloma_in_the_US\"><\/span><strong>\u00bfCu\u00e1l es la prevalencia del mieloma m\u00faltiple en los EE. UU.?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>De acuerdo a <a href=\"https:\/\/www.cancer.org\/cancer\/types\/multiple-myeloma\/about\/key-statistics.html\">Sociedad Americana del C\u00e1ncer<\/a> Se estima que en 2024 se producir\u00e1n m\u00e1s de 35.000 nuevos casos de mieloma m\u00faltiple y alrededor de 12.540 muertes.&nbsp;<\/p>\n\n\n\n<p>El mieloma m\u00faltiple es m\u00e1s com\u00fan en personas mayores, con una edad promedio de 65 a 69 a\u00f1os.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_Can_IVIG_Therapy_Help_Multiple_Myeloma_Patients\"><\/span><strong>\u00bfC\u00f3mo puede la terapia con IgIV ayudar a los pacientes con mieloma m\u00faltiple?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La terapia con IgIV se ha utilizado durante d\u00e9cadas para tratar diversas enfermedades relacionadas con el sistema inmunitario, incluido el mieloma m\u00faltiple.&nbsp;<\/p>\n\n\n\n<p>En el mieloma m\u00faltiple, la terapia con IgIV proporciona temporalmente a los pacientes una serie de anticuerpos y ayuda a mejorar su funci\u00f3n inmunitaria general. Estos anticuerpos reconocen y combaten las infecciones que el sistema inmunitario del paciente no puede controlar.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_Does_IVIG_Therapy_Work\"><\/span><strong>\u00bfC\u00f3mo funciona la terapia con IgIV?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"420\" height=\"270\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/multiple-myeloma.jpg\" alt=\"Multiple myeloma concept illustration\" class=\"wp-image-26670\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/multiple-myeloma.jpg 420w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/multiple-myeloma-300x193.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/multiple-myeloma-86x55.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/multiple-myeloma-167x107.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/multiple-myeloma-280x180.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/multiple-myeloma-370x238.jpg 370w\" sizes=\"auto, (max-width: 420px) 100vw, 420px\" \/><\/figure>\n<\/div>\n\n\n<p>Aunque se desconoce el mecanismo de acci\u00f3n exacto de la terapia con IgIV, seg\u00fan estudios, potencia la respuesta inmunitaria contra las infecciones. En pacientes con mieloma m\u00faltiple, la IgIV puede ejercer los siguientes efectos beneficiosos:<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Reduce la frecuencia de infecciones recurrentes<\/strong><\/h4>\n\n\n\n<p>La terapia con IgIV fortalece el sistema inmunitario del paciente al proporcionarle anticuerpos. Diversos estudios indican que la terapia con IgIV puede ayudar a reducir la frecuencia de infecciones recurrentes, incluidas las de grado 3, en pacientes con mieloma m\u00faltiple.&nbsp;<\/p>\n\n\n\n<p>Por ejemplo, un estudio publicado en <a href=\"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/4\/6\/440\/729755\/IVIg-Use-Associated-with-Ten-Fold-Reduction-of\">&quot;Descubrimiento del c\u00e1ncer de sangre&quot;<\/a> Se inform\u00f3 que la terapia con inmunoglobulina intravenosa (IgIV) puede reducir el riesgo de infecciones de grado 3 y 5 mediante 90% en pacientes con mieloma m\u00faltiple en reca\u00edda o refractario. Los investigadores concluyeron adem\u00e1s que la terapia con IgIV debe administrarse durante y despu\u00e9s del tratamiento.<\/p>\n\n\n\n<div  id=\"call-to-action-3521701a878da4f808c94953d1bc2b27\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tPregunte sobre la infusi\u00f3n de IgIV en el hogar\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Programar una consulta<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Proporciona inmunidad pasiva&nbsp;<\/strong><\/h4>\n\n\n\n<p>La IgIV proporciona inmunidad pasiva a los pacientes con MM, lo que significa que se infunden anticuerpos prefabricados obtenidos de donantes para combatir las infecciones. A diferencia de las vacunas, que estimulan la producci\u00f3n de anticuerpos en las c\u00e9lulas plasm\u00e1ticas, la terapia con IgIV complementa el organismo del paciente con anticuerpos esenciales que brindan protecci\u00f3n inmediata y act\u00faan contra las infecciones.&nbsp;<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Ejerce efectos anticancer\u00edgenos y antiinflamatorios.&nbsp;<\/strong><\/h4>\n\n\n\n<p>La IgIV es conocida por sus propiedades antiinflamatorias, que ayudan a regular el sistema inmunol\u00f3gico hiperactivo en diversos trastornos autoinmunes.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2020.01816\/full\">Investigaciones recientes<\/a> En el Centro Oncol\u00f3gico MD Anderson se revel\u00f3 que la terapia con IgIV disminuy\u00f3 el crecimiento de c\u00e9lulas de mieloma (c\u00e9lulas plasm\u00e1ticas cancerosas) y caus\u00f3 la muerte celular. Con base en estos hallazgos, el investigador concluy\u00f3 que la terapia con IgIV puede inducir efectos anticancer\u00edgenos y que a\u00f1adirla a... <a href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/darzalex-and-its-role-in-treating-multiple-myeloma\/\">tratamiento est\u00e1ndar del mieloma<\/a> Podr\u00eda ayudar a obtener mejores resultados.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Is_the_Standard_Dose_of_IVIG_for_Multiple_Myeloma_Patients\"><\/span><strong>\u00bfCu\u00e1l es la dosis est\u00e1ndar de IgIV para pacientes con mieloma m\u00faltiple?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La IgIV se administra generalmente a pacientes con mieloma cada 3 o 4 semanas a una dosis de 0,4 gramos por kilogramo. La frecuencia de administraci\u00f3n de IgIV puede variar seg\u00fan los niveles de inmunoglobulina estables de la persona.&nbsp;<\/p>\n\n\n\n<p>Por ejemplo, algunos pacientes pueden requerir terapia con IgIV una vez al mes, mientras que otros pueden necesitarla con mayor frecuencia.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Who_Can_Benefit_From_IVIG_Therapy\"><\/span><strong>\u00bfQui\u00e9n puede beneficiarse de la terapia con IgIV?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pacientes con mieloma m\u00faltiple que tienen <a href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/hypogammaglobulinemia\/\">hipogammaglobulinemia<\/a> (bajo nivel de anticuerpos en la sangre) y son altamente susceptibles a infecciones recurrentes o graves pueden beneficiarse de la terapia con IgIV.&nbsp;<\/p>\n\n\n\n<p>De manera similar, los pacientes con MM que se someten a quimioterapia y trasplantes de c\u00e9lulas madre tambi\u00e9n pueden obtener beneficios de la terapia con IgIV, ya que estos tratamientos intensivos afectan el sistema inmunol\u00f3gico y aumentan el riesgo de infecciones.&nbsp;<\/p>\n\n\n\n<p>Por ejemplo, un estudio de cohorte demostr\u00f3 que el uso de IgIV durante terapias inmunol\u00f3gicas fue significativamente... <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0006497123132678\">reduce las infecciones de todos los grados en 40%<\/a>.&nbsp;<\/p>\n\n\n\n<p>Es importante destacar que la terapia con IgIV no es un tratamiento \u00fanico para el mieloma m\u00faltiple. Se utiliza como terapia de apoyo para reducir el riesgo de infecciones en pacientes con mieloma m\u00faltiple.<\/p>","protected":false},"excerpt":{"rendered":"<p>La IgIV se utiliza como terapia de apoyo en pacientes con mieloma m\u00faltiple. El mieloma m\u00faltiple es un tipo raro de c\u00e1ncer de la sangre que se forma en las c\u00e9lulas plasm\u00e1ticas, un tipo de gl\u00f3bulo blanco que produce anticuerpos para combatir infecciones en condiciones normales.\u00a0<\/p>","protected":false},"author":25,"featured_media":26669,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[7],"tags":[31],"class_list":["post-26668","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ivig","tag-dr-mark-alfonso"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IVIG for Multiple Myeloma (MM) - AmeriPharma\u00ae Specialty Care<\/title>\n<meta name=\"description\" content=\"Learn how IVIG is used as supportive therapy in patients with multiple myeloma. Topics include the beneficial effects of IVIG, dosing, and more.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IVIG for Multiple Myeloma (MM) - AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"og:description\" content=\"Learn how IVIG is used as supportive therapy in patients with multiple myeloma. Topics include the beneficial effects of IVIG, dosing, and more.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-multiple-myeloma-mm\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-18T15:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Mark Alfonso, PharmD, BCMTMS\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Mark Alfonso, PharmD, BCMTMS\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/ivig\\\/ivig-for-multiple-myeloma-mm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/ivig\\\/ivig-for-multiple-myeloma-mm\\\/\"},\"author\":{\"name\":\"Dr. Mark Alfonso, PharmD, BCMTMS\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/person\\\/91fbbfa457730010998bc804c0467310\"},\"headline\":\"IVIG for Multiple Myeloma (MM)\",\"datePublished\":\"2024-10-18T15:30:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/ivig\\\/ivig-for-multiple-myeloma-mm\\\/\"},\"wordCount\":839,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/ivig\\\/ivig-for-multiple-myeloma-mm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/ivig-patient.jpg\",\"keywords\":[\"Dr. Mark Alfonso\"],\"articleSection\":[\"IVIG\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/ivig\\\/ivig-for-multiple-myeloma-mm\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/ivig\\\/ivig-for-multiple-myeloma-mm\\\/\",\"name\":\"IVIG for Multiple Myeloma (MM) - AmeriPharma\u00ae Specialty Care\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/ivig\\\/ivig-for-multiple-myeloma-mm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/ivig\\\/ivig-for-multiple-myeloma-mm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/ivig-patient.jpg\",\"datePublished\":\"2024-10-18T15:30:00+00:00\",\"description\":\"Learn how IVIG is used as supportive therapy in patients with multiple myeloma. Topics include the beneficial effects of IVIG, dosing, and more.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/ivig\\\/ivig-for-multiple-myeloma-mm\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/ivig\\\/ivig-for-multiple-myeloma-mm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/ivig\\\/ivig-for-multiple-myeloma-mm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/ivig-patient.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/ivig-patient.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Nurse with patient receiving IVIG therapy for multiple myeloma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/ivig\\\/ivig-for-multiple-myeloma-mm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IVIG for Multiple Myeloma (MM)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/person\\\/91fbbfa457730010998bc804c0467310\",\"name\":\"Dr. Mark Alfonso, PharmD, BCMTMS\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g\",\"caption\":\"Dr. Mark Alfonso, PharmD, BCMTMS\"},\"description\":\"Dr. Mark Alfonso, PharmD was born and raised in Pueblo, CO. He received his pharmacy degree from the University of Colorado School of Pharmacy at the Anschutz Medical Campus in 2010. He was board certified in medication therapy management in 2022. The most rewarding part of his job is helping to answer patient questions and concerns. His areas of expertise are community pharmacy and medication therapy management. In his free time, he enjoys reading and running.\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/mark-alfonso\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IgIV para el mieloma m\u00faltiple (MM) - AmeriPharma\u00ae Atenci\u00f3n especializada","description":"Aprenda c\u00f3mo se utiliza la IgIV como terapia de apoyo en pacientes con mieloma m\u00faltiple. Los temas incluyen los efectos beneficiosos de la IgIV, su dosificaci\u00f3n y m\u00e1s.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"es_MX","og_type":"article","og_title":"IVIG for Multiple Myeloma (MM) - AmeriPharma\u00ae Specialty Care","og_description":"Learn how IVIG is used as supportive therapy in patients with multiple myeloma. Topics include the beneficial effects of IVIG, dosing, and more.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-multiple-myeloma-mm\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2024-10-18T15:30:00+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg","type":"image\/jpeg"}],"author":"Dr. Mark Alfonso, PharmD, BCMTMS","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Mark Alfonso, PharmD, BCMTMS","Est. reading time":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/ivig\/ivig-for-multiple-myeloma-mm\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/ivig\/ivig-for-multiple-myeloma-mm\/"},"author":{"name":"Dr. Mark Alfonso, PharmD, BCMTMS","@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/person\/91fbbfa457730010998bc804c0467310"},"headline":"IVIG for Multiple Myeloma (MM)","datePublished":"2024-10-18T15:30:00+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/ivig\/ivig-for-multiple-myeloma-mm\/"},"wordCount":839,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/ivig\/ivig-for-multiple-myeloma-mm\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg","keywords":["Dr. Mark Alfonso"],"articleSection":["IVIG"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/ivig\/ivig-for-multiple-myeloma-mm\/","url":"https:\/\/ameripharmaspecialty.com\/ivig\/ivig-for-multiple-myeloma-mm\/","name":"IgIV para el mieloma m\u00faltiple (MM) - AmeriPharma\u00ae Atenci\u00f3n especializada","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/ivig\/ivig-for-multiple-myeloma-mm\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/ivig\/ivig-for-multiple-myeloma-mm\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg","datePublished":"2024-10-18T15:30:00+00:00","description":"Aprenda c\u00f3mo se utiliza la IgIV como terapia de apoyo en pacientes con mieloma m\u00faltiple. Los temas incluyen los efectos beneficiosos de la IgIV, su dosificaci\u00f3n y m\u00e1s.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/ivig\/ivig-for-multiple-myeloma-mm\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/ivig\/ivig-for-multiple-myeloma-mm\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/ivig\/ivig-for-multiple-myeloma-mm\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg","width":1280,"height":853,"caption":"Nurse with patient receiving IVIG therapy for multiple myeloma"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/ivig\/ivig-for-multiple-myeloma-mm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/"},{"@type":"ListItem","position":2,"name":"IVIG for Multiple Myeloma (MM)"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/es\/#website","url":"https:\/\/ameripharmaspecialty.com\/es\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/es\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/person\/91fbbfa457730010998bc804c0467310","name":"Dr. Mark Alfonso, PharmD, BCMTMS","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g","caption":"Dr. Mark Alfonso, PharmD, BCMTMS"},"description":"El Dr. Mark Alfonso, doctor en farmacia, naci\u00f3 y creci\u00f3 en Pueblo, Colorado. Obtuvo su t\u00edtulo en farmacia en la Facultad de Farmacia de la Universidad de Colorado, en el Campus M\u00e9dico Anschutz, en 2010. Obtuvo su certificaci\u00f3n en gesti\u00f3n de terapias farmacol\u00f3gicas en 2022. Lo m\u00e1s gratificante de su trabajo es ayudar a responder las preguntas e inquietudes de los pacientes. Sus \u00e1reas de especializaci\u00f3n son la farmacia comunitaria y la gesti\u00f3n de terapias farmacol\u00f3gicas. En su tiempo libre, disfruta de la lectura y correr.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/mark-alfonso\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Mark Alfonso, PharmD, BCMTMS","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/mark-alfonso\/"},"uagb_comment_info":0,"uagb_excerpt":"IVIG is used as a supportive therapy in patients with multiple myeloma. Multiple myeloma is a rare type of blood cancer that forms in plasma cells, a type of white blood cell that produces antibodies to fight infections under normal conditions.\u00a0","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/10\/ivig-patient.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Mark Alfonso, PharmD, BCMTMS","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/mark-alfonso\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/ivig\/\" rel=\"category tag\">IVIG<\/a>","rttpg_excerpt":"IVIG is used as a supportive therapy in patients with multiple myeloma. Multiple myeloma is a rare type of blood cancer that forms in plasma cells, a type of white blood cell that produces antibodies to fight infections under normal conditions.\u00a0","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/26668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=26668"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/26668\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/26669"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=26668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=26668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=26668"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}